Symmetry Medical (NYSE:SMA) saw its 2nd-quarter profits plunge more than 28% on flat sales and lowered its outlook for the balance of the year.
Sales are flat, profits plunge in the 2nd quarter for Symmetry Medical
2012
Biomet swings to Q4 black, pares fiscal 2013 losses
Biomet said it posted black ink during the 4th quarter and cut its losses for fiscal 2013, reporting a 1.0 % decline in large joint reconstruction sales.
The privately held medical device company, which is said to be considering an IPO or sale, is closely watched as a bellwether for the orthopedic market, which has been bedeviled in recent years by falling procedure volumes for hip and knee replacements.
EDAP’s losses widen, sales increase in 2012
EDAP (NSDQ:EDAP) posted a slight bump in sales but a dramatic increase in losses for the fiscal year of 2012
The French device maker posted year-end losses of $9.7 million, or 55¢ per diluted share, on sales of $33.7 million. That compares with 2011 losses of $1.3 million, or 10¢ per diluted share, on sales of $31.2 million.
FDA accepts Edap’s Ablatherm PMA application
Edap (NSDQ:EDAP) said the FDA accepted its pre-market approval application for its Ablatherm ultrasound prostate cancer treatment, backed by data from its Enlight investigational device exemption study.
The Vaulx-en-Velin, France-based medical device company also reported that its losses increased by a whopping 646% during the 2012, on an 8% sales increase.
FDA approves 1st Type 2 diabetes drug | Wall Street Beat
The FDA approved a 1st-of-its-kind treatment for Type 2 diabetes, Johnson & Johnson‘s (NYSE:JNJ) Invokana, with the federal watchdog agency citing it as a pioneer in a new class of diabetes drug.
Sanuwave slashes workforce by 65%, but pares losses by more than a third
Sanuwave Health (OTC:SNWV) laid off more than ⅓ of its workforce in its quest to pare its 2012 losses, according to a regulatory filing, shrinking from 28 employees to 10.
Kips Bay rises on FDA trial approval, despite losses in sales and revenue
Medical device maker Kips Bay Medical (NSDQ:KIPS) saw widening losses and sinking sales during its most recent quarter, but the company marked an important win with FDA approval to complete full enrollment in the U.S. arm of a feasibility study.
AtriCure slips on missed Q4, 2012 results
AtriCure (NSDQ:ATRC) reported wider losses for 2012 and missed Wall Street’s expectations with its Q4 and full-year results, sending shares down on The Street last week.
The West Chester, Ohio-based medical device company posted losses of $2.0 million, or 12¢ per share, on sales of $18.4 million for the 3 months ended Dec. 31, 2012, for top-line growth of 9.6% and a loss reduction of 2.9%.
Diabetes: Insulet gains on strong Q4, lands FDA win
Hansen Medical’s Q4 profits rise on patent deal, but 2012 losses still widen
Hansen Medical (NSDQ:HNSN) managed to eke out a profit during the 4th quarter on the sale and licensing of some of its patents, but still posted wider losses for 2012, sending shares down on Wall Street last week.
UPDATE: NxStage Medical CEO on its Wall-Street-beating Q4 results
NxStage Medical (NSDQ:NXTM) shares jumped nearly 8% today after the medical device company reported Wall-Street-beating results for the 4th quarter and 2012.
